株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

3SBio Inc.:製品パイプライン分析

3SBio Inc. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 200917
出版日 ページ情報 英文 81 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
3SBio Inc.:製品パイプライン分析 3SBio Inc. - Product Pipeline Review - 2016
出版日: 2016年05月25日 ページ情報: 英文 81 Pages
概要

3SBio Inc.は、中国においてバイオ医薬品を研究、開発、製造するバイオテクノロジー企業です。

当レポートでは、3SBio Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを提供しています。

3SBio Inc.の基本情報

  • 3SBio Inc.の概要
  • 主要情報
  • 企業情報

3SBio Inc.:R&Dの概要

  • 主な治療範囲

3SBio Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • 併用療法モダリティ
  • パートナー製品
    • パートナー製品/併用療法モダリティ

3SBio Inc.:パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 第?相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第?相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • IND/CTA に申請された製品/併用療法モダリティ
    • 前臨床段階にある製品/併用療法モダリティ

3SBio Inc.:薬剤プロファイル

3SBio Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

3SBio Inc.:最近のパイプライン動向

3SBio Inc.:休止中のプロジェクト

3SBio Inc.:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • NuLeusin

企業発表

3SBio Inc.:本社と子会社の所在地

  • 本社
  • その他の事業所・子会社

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08051CDB

Summary

Global Markets Direct's, '3SBio Inc. - Product Pipeline Review - 2016', provides an overview of the 3SBio Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by 3SBio Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of 3SBio Inc.
  • The report provides overview of 3SBio Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses 3SBio Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features 3SBio Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate 3SBio Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for 3SBio Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 3SBio Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • 3SBio Inc. Snapshot
    • 3SBio Inc. Overview
    • Key Information
    • Key Facts
  • 3SBio Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • 3SBio Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • 3SBio Inc. - Pipeline Products Glance
    • 3SBio Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • 3SBio Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • 3SBio Inc. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
  • 3SBio Inc. - Drug Profiles
    • (clindamycin phosphate + tretinoin)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AT-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SSS-06
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SSS-07
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (tipiracil hydrochloride + trifluridine)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cinacalcet hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • colestilan chloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • eltrombopag olamine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nadroparin calcium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PEG-EPO
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PEG-irinotecan
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegadricase
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sevelamer carbonate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trelagliptin succinate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (betamethasone valerate + calcipotriene)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • APG-1387
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • desonide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DJ-5
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DNP-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ferric citrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fondaparinux sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PMC-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit HIF-PH for Renal Anemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SSS-08
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • thrombopoietin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TTAC-0001
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • 3SBio Inc. - Pipeline Analysis
    • 3SBio Inc. - Pipeline Products by Target
    • 3SBio Inc. - Pipeline Products by Route of Administration
    • 3SBio Inc. - Pipeline Products by Molecule Type
    • 3SBio Inc. - Pipeline Products by Mechanism of Action
  • 3SBio Inc. - Recent Pipeline Updates
  • 3SBio Inc. - Dormant Projects
  • 3SBio Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • NuLeusin
  • 3SBio Inc. - Company Statement
  • 3SBio Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • 3SBio Inc., Key Information
  • 3SBio Inc., Key Facts
  • 3SBio Inc. - Pipeline by Indication, 2016
  • 3SBio Inc. - Pipeline by Stage of Development, 2016
  • 3SBio Inc. - Monotherapy Products in Pipeline, 2016
  • 3SBio Inc. - Combination Treatment Modalities in Pipeline, 2016
  • 3SBio Inc. - Partnered Products in Pipeline, 2016
  • 3SBio Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • 3SBio Inc. - Phase III, 2016
  • 3SBio Inc. - Phase II, 2016
  • 3SBio Inc. - Phase I, 2016
  • 3SBio Inc. - IND/CTA Filed, 2016
  • 3SBio Inc. - Preclinical, 2016
  • 3SBio Inc. - Pipeline by Target, 2016
  • 3SBio Inc. - Pipeline by Route of Administration, 2016
  • 3SBio Inc. - Pipeline by Molecule Type, 2016
  • 3SBio Inc. - Pipeline Products by Mechanism of Action, 2016
  • 3SBio Inc. - Recent Pipeline Updates, 2016
  • 3SBio Inc. - Dormant Developmental Projects,2016
  • 3SBio Inc. - Discontinued Pipeline Products, 2016
  • 3SBio Inc., Other Locations
  • 3SBio Inc., Subsidiaries

List of Figures

  • 3SBio Inc. - Pipeline by Top 10 Indication, 2016
  • 3SBio Inc. - Pipeline by Stage of Development, 2016
  • 3SBio Inc. - Monotherapy Products in Pipeline, 2016
  • 3SBio Inc. - Combination Treatment Modalities in Pipeline, 2016
  • 3SBio Inc. - Partnered Products in Pipeline, 2016
  • 3SBio Inc. - Pipeline by Top 10 Target, 2016
  • 3SBio Inc. - Pipeline by Route of Administration, 2016
  • 3SBio Inc. - Pipeline by Molecule Type, 2016
  • 3SBio Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top